Eli Lilly & Company

Eli Lilly & Company

Eli Lilly & Company

Overview
Date Founded

1901

Headquarters

LILLY CORPORATE CENTER, INDIANAPOLIS, IN, 462850002

Type of Company

Public

Employees (Worldwide)

33.6K

Industries

Pharmaceuticals
Hospitals & Patient Services
Medical Support Services
Biotechnology

Company Description

Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. Its products include Forteo, Adrica, BAQSIMI, Basaglar and Glucagn. The company was founded by Eli Lilly on May 1876 and is headquartered in Indianapolis, IN.

Contact Data
Trying to get in touch with decision makers at Eli Lilly & Company? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Director, President & Chief Executive Officer

Chief Financial Officer & Senior Vice President

Senior Vice President & General Counsel

Chief Scientific Officer

Senior Vice President & Chief Scientific Officer & President of Lilly Research Laboratories

President, International Operations

Senior Vice President & President, Lilly Bio-Medicines

Senior Vice President

Senior Vice President, Human Resources & Diversity

Senior Vice President & President, Lilly Oncology

Board of Directors

Senior Advisor at Southern Capital Group Pte Ltd.

Co-Founder at Tango Therapeutics, Inc.

Operating Partner at Advent International Corp.

Former Chairman & Chief Executive Officer at United Parcel Service, Inc.

Senior Managing Director at Brock Capital Group LLC

Paths to Eli Lilly & Company
Potential Connections via
Relationship Science
You
Eli Lilly & Company
Owners & Shareholders
Details Hidden

Founded in 1937 by J.K. Lilly, Sr. and his sons J.K. Lilly, Jr. and Eli Lilly, the Lilly Endowment, Inc. is a private, non-profit philanthropic foundation located in Indianapolis, Indiana. The Lilly Endowment supports the causes of community development, education and religion

Details Hidden

PRIMECAP Management aims to provide superior long-term investment results by utilizing fundamental research and bottom-up stock picking to construct portfolios. The firm looks for stocks that will outperform the market over a three to five-year horizon. PRIMECAP Management does not have a committee or small group that decides on whether or not to invest in an idea. Each portfolio manager makes an individual decision whether or not to invest in new ideas.

Details Hidden

Wellington Management's investment services rely on their extensive independent research and include portfolio management styles and approaches in equities, fixed income securities, currencies and commodities, as well as asset allocation across these categories. The firm has a number of different disciplines when approaching research and these include asset allocation analysts, currency analysts, data scientists, factor analysts, fixed income credit analysts, fixed income market analysts, global industry analysts and research associates, macroanalysts, quantitative analysts and technical analysts. Wellington Management's portfolio management teams often include dedicated analysts who evaluate securities and other instruments for suitability based on the team's investment approach. The firm supplements their internal research with external research from sources such as broker/dealers and third-party research firms. These sources typically provide data, research and analysis and may serve as a gauge of market consensus.

Recent Transactions
Details Hidden

Eli Lilly & Company purchases Dermira, Inc.

Details Hidden

Eddingpharm (Cayman), Inc. purchases Eli Lilly & Co. /Ceclor Manufacturing Facility from Eli Lilly & Company

Details Hidden

Eli Lilly & Company purchases Loxo Oncology, Inc.

Insider Transactions
Details Hidden
Details Hidden
Details Hidden
Transaction Advisors
Legal Advisor

Advised onEli Lilly & Company purchases Elanco Tiergesundheit AG from Novartis AG

Legal Advisor

Advised onEli Lilly & Company purchases ImClone LLC

Legal Advisor

Advised onEli Lilly & Company purchases ICOS Corporation

Legal Advisor

Advised onEli Lilly & Company purchases Elanco Tiergesundheit AG from Novartis AG

Legal Advisor

Advised onEli Lilly & Company purchases Elanco Tiergesundheit AG from Novartis AG

Legal Advisor

Advised onEli Lilly & Company purchases ImClone LLC

Advisors & Consultants
Legal Advisor

Partner at Latham & Watkins LLP

Legal Advisor

Partner at Paul, Weiss, Rifkind, Wharton & Garrison LLP

Legal Advisor

Partner at Paul, Weiss, Rifkind, Wharton & Garrison LLP

Clients

OPKO Health, Inc. engages in the provision of healthcare services. It operates through the following segments: Diagnostics, Pharmaceuticals, and Corporate. The Diagnostics segment include clinical laboratory operations of BioReference, as well as point-of-care operations. The Pharmaceuticals segment includes comprises pharmaceutical operations in Chile, Mexico, Ireland, Israel, and Spain and pharmaceutical research and development operations. The company was founded in October 1991 and is headquartered in Miami, FL.

United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening diseases. It markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. The firm also involves in the research and development of new indications and delivery devices for its product, and for the organ transplantation-related technologies. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

Cipla Ltd. engages in the manufacture and distribution of healthcare products and bulk drugs. It operates through the following segments: Pharmaceuticals and New Ventures. The Pharmaceuticals segment develops, manufactures, sells and distributes generic or branded generic medicines as well as active pharmaceutical ingredients. The New Ventures segment includes the operations of the two wholly owned subsidiaries, Cipla Health Ltd., a consumer healthcare company and Cipla BioTec Pvt. Ltd, which is into the business of Biosimilars. The company was founded by Khwaja Abdul Hamied in 1935 and is headquartered in Mumbai, India.

Key Stats and Financials As of 2019
Market Capitalization
$152B
Total Enterprise Value
$137B
Earnings Per Share
$4.96
Revenue
$22.3B
Net Profit
$4.64B
EBITDAMargin
31.46%
Enterprise Value EBITDAOperating
19.36x
TEVNet Income
29.44x
Debt TEV
0.12x
Enterprise Value Sales
6.12x
Total Equity
$2.7B
Total Debt
$15.9B
EBITDA
$7.02B
Three Year Compounded Annual Growth Rate Of Revenue
1.69%
Five Year Compounded Annual Growth Rate Of Revenue
2.62%
Non-Profit Donations & Grants
Non-Profit Donations & Grants Received
Political Donations
$500
2014
$200
2014
Investments
Details Hidden

CureVac AG develops tumor immunotherapy. It offers RNA optimization, RNActive, RNArt, RNAdjuvant, in house GMP production, research and development services, and PureMessenger applications. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany.

Details Hidden

NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lie Ping Chen in September 2015 and is headquartered in Beltsville, MD.

Details Hidden

Immunocore Ltd. operates as a biotechnology company. It focuses on the discovery and development of novel T cell receptor-based drugs. The firm ImmTAC technology is bi-functional that combine monoclonal T cell receptor targeting technology with a clinically-validated, potent therapeutic mechanism of action. It has established regulatory pathways approved by the food and drug administration, medicines and healthcare products regulatory agency that will form the basis for development of future ImmTAC programs. The company was founded by Bent Jakobsen in 2008 and is headquartered in Abingdon, the United Kingdom.

Investors
Details Hidden

Partner at SR One Ltd.

Details Hidden

Chairman-Vant Division at Roivant Sciences, Inc.

Details Hidden

Investor at Fluidigm Corp.

Suppliers
Computer Task Group, Inc. IT Consulting & Services | Buffalo, NY

CTG's mission is to provide IT services and solutions that add real business value to our customers while creating professional opportunities for our employees and value for our shareholders. CTG's Vision CTG's vision is to be recognized as a leading provider of value-added IT services and solutions in our selected markets. CTG's Values Integrity as the essential foundation of all business and personal interactions Individual initiative in personal and professional development A sense of personal pride in our work and satisfaction in serving our clients and our organization Clear, unambiguous understanding of our clients' needs and expectations Commitment to Quality Our commitment to quality ensures that we focus on continuous improvement, employ proven methodologies and best practices, and deliver services that meet client expectations and requirements. CTG is one of a few IT services companies using a ISO 9001-certified management system.

R.R. Donnelley & Sons Co. Computer Software | Chicago, IL

RR Donnelley (Nasdaq:RRD) is a global provider of integrated communications. The company works collaboratively with more than 60,000 customers worldwide to develop custom communications solutions that reduce costs, drive top line growth, enhance ROI and ensure compliance. Drawing on a range of proprietary and commercially available digital and conventional technologies deployed across four continents, the company employs a suite of leading Internet based capabilities and other resources to provide premedia, printing, logistics and business process outsourcing services to clients in virtually every private and public sector.

Alexandria Real Estate Equities, Inc. Trusts & Funds | Pasadena, CA

Alexandria Real Estate Equities, Inc. is an urban office real estate investment trust, which engages in the ownership, operation, development, and redevelopment of life science and technology properties. It also provides a space for lease to the life science and technology industries which are primarily located in AAA urban innovation cluster locations. The company was founded by Alan D. Gold, Gary A. Kreitzer, Joel S. Marcus, and Jerry M. Sudarsky in October 1994 and is headquartered in Pasadena, CA.

Competitors
Merck & Co., Inc. Pharmaceuticals - Kenilworth, NJ

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Amgen, Inc. Biotechnology - Thousand Oaks, CA

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Awards & Honors
Rank #141
2016
Fortune Magazine - Fortune 1000 Companies
Sponsored by Fortune Magazine
Rank #141
2016
Fortune Magazine - Fortune 500 Companies
Sponsored by Fortune Magazine
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Eli Lilly & Company. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Eli Lilly & Company's profile does not indicate a business or promotional relationship of any kind between RelSci and Eli Lilly & Company.